The polymerase chain reaction (PCR) is a highly efficient gene amplification procedure which is increasingly being applied to the safety assessment of nucleic acid (NA) medicines such as gene therapies and DNA vaccines.
Although clinical experience is limited, a number of potential safety issues exist with these new compounds including toxicity associated with the expression of encoded gene products, autoimmunity due to the induction of anti-DNA antibodies and insertional mutagenesis. PCR enables these questions to be addressed and provides data on mRNA expression, biodistribution and integration.
In this review the use of PCR methodologies in the preclinical safety evaluation of NA medicines is discussed. Particular consideration is given to the issues surrounding the use of PCR in regulatory toxicology, including sensitiv-ity requirements, cross-contamination problems, tissue sampling procedures and good laboratory practice (GLP) compliance. In addition, the use of a PCR-based assay to demonstrate the integration of DNA vector into host DNA is described.
As the use of PCR in the development of NA medicines will undoubtedly increase over the next few years, it is important that pathologists and toxicologists familiarise themselves with the principles and applications of this technique.
1 Saiki RK , Scharf S , Faloona F , et al. Enzymatic amplification of beta-globin genomic sequences and restriction site analysis for diagnosis of sickle cell anemia . Science1985; 230: 1350-1354 .
2.
2 Mullis K , Faloona F , Scharf S , et al. Specific enzymatic amplification of DNA in vitro: the polymerase chain reaction . Cold Spring Harbor Symposia on Quantitative Biology1986; 51 Pt 1: 263-273 .
3.
3 Saiki RK , Gelfand DH , Stoffel S , et al. Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase . Science1988; 239: 487-491 .
4.
4 Erlich HA , Gelfand D , Sninsky JJ.Recent advances in the polymerase chain reaction . Science1991; 252: 1643-1651 .
5.
5 Donnelly JJ , Ulmer JB , Shiver JW , Liu MA . DNA vaccines . Annual Review of Immunology1997; 15: 617-648 .
6.
6 Monteith DK , Levin AA . Synthetic oligonucleotides: the development of antisense therapeutics . Toxicologic Pathology1999; 27: 8-13 .
7.
7 Stull RA , Szoka FC, Jr.Antigene, ribozyme and aptamer nucleic acid drugs: progress and prospects . Pharmaceu-tical Research1995; 12: 465-483 .
8.
8 Pilaro AM , Serabian MA . Preclinical development strategies for novel gene therapeutic products . Toxicolo-gic Pathology1999; 27: 4-7 .
9.
9 Palu G , Bonaguro R , Marcello A . In pursuit of new developments for gene therapy of human diseases . Journal of Biotechnology1999; 68: 1-13 .
10.
10 Tang DC , DeVit M , Johnston SA . Genetic immunization is a simple method for eliciting an immune response . Nature1992; 356: 152-154 .
11.
11 Ellington AD , Szostak JW . In vitro selection of RNA molecules that bind specific ligands . Nature1990; 346: 818-822 .
12.
12 Smith HA . Regulatory considerations for nucleic acid vaccines . Vaccine1994; 12: 1515-1519 .
13.
13 Maniatis TE , Fritsch F , Sambrook J . Molecular Cloning: A Laboratory Manual. New York: Cold Spring Harbour Laboratories, Cold Spring Harbour , 1990.
14.
14 Baumforth KR , Nelson PN , Digby JE , O'Neil JD , Murray PG . Demystified... the polymerase chain reaction . Molecular Pathology1999; 52: 1-10 .
15.
15 Templeton NS . The polymerase chain reaction. History, methods, and applications . Diagnostic Molecular Pathol-ogy1992; 1: 58-72 .
16.
16 Pan LX , Diss TC , Isaacson PG . The polymerase chain reaction in histopathology . Histopathology1995; 26: 201-217 .
17.
17 Wilkinson M . Purification of RNA. In: Brown TA , ed. Essential Molecular Biology; A Practical Approach. Oxford: Oxford University Press , 1991; 69-87.
18.
18 Mitsuhashi M . Technical report: Part 2. Basic require-ments for designing optimal PCR primers . Journal of Clinical Laboratory Analysis1996; 10: 285-293 .
19.
19 Andrews AT . Electrophoresis of nucleic acids. In: Brown TA , ed. Essential Molecular Biology; A Practical Ap-proach. Oxford: Oxford University Press , 1991; 89-124.
20.
20 Holland PM , Abramson RD , Watson R , Gelfand DH . Detection of specific polymerase chain reaction product by utilizing the 5'-3' exonuclease activity of Thermus aquaticus DNA polymerase . Proceedings of the National Academy of Sciences of the United States of America 1991; 88: 7276-7280 .
21.
21 Lee LG , Connell CR , Bloch W . Allelic discrimination by nick-translation PCR with fluorogenic probes . Nucleic Acids Research1993; 21: 3761-3766 .
22.
22 Pilaro AM . Safety evaluation of gene therapies: past, present and future. Available at http://www.fda.gov/cber/summaries/asgtO6O999ap.ppt. 1999; (Abstract).
23.
23 Parker SE , Borellini F , Wenk ML , et al. Plasmid DNA malaria vaccine: tissue distribution and safety studies in mice and rabbits . Human Gene Therapy1999; 10: 741-758 .
24.
24 Griffiths SA , Lumley CE . Non-clinical safety studies for biotechnologically-derived pharmaceuticals: con-clusions from an international workshop . Human and Experimental Toxicology1998; 17: 63-83 .
25.
25 FDA . Panel to investigate possible germline transfer in gene therapy work. FDA Week 1997; 1-2.
26.
26 Tsukui T , Kanegae Y , Saito I , Toyoda Y . Transgenesis by adenovirus-mediated gene transfer into mouse zona-free eggs . Nature Biotechnology1996; 14: 982-985 .
27.
27 Ye X , Gao GP , Pabin C , Raper SE , Wilson JM . Evaluating the potential of germ line transmission after intravenous administration of recombinant adenovirus in the C3H mouse . Human Gene Therapy1998; 9: 2135-2142 .
28.
28 Kurth R . Risk potential of the chromosomal insertion of foreign DNA . Annals of the New York Academy of Sciences1995; 772: 140-151 .
29.
29 Wolff JA , Ludtke JJ , Acsadi G , Williams P , Jani A . Long-term persistence of plasmid DNA and foreign gene expression in mouse muscle . Human Molecular Genetics1992; 1: 363-369 .
30.
30 Wigler M , Pellicer A , Silverstein S , Axel R , Urlaub G , Chasin L . DNA-mediated transfer of the adenine phosphoribosyltransferase locus into mammalian cells . Proceedings of the National Academy of Sciences of the United States of America 1979; 76: 1373-1376 .
31.
31 European Agency for the Evaluation of Medicinal Products . Safety studies for gene therapy products: annex to note for guidance on gene therapy product quality aspects in the production of vectors and genetically modified somatic cells. 1998; SWP/112/98: 1-7 (Abstract).
32.
32 Nichols WW , Ledwith BJ , Manam SV , Troilo PJ . Potential DNA vaccine integration into host cell genome . Annals of the New York Academy of Sciences1995; 772: 30-39 .
33.
33 Izsvak Z , Ivics Z . Two-stage ligation-mediated PCR enhances the detection of integrated transgenic DNA . Biotechniques1993; 15: 814-818 .
34.
34 Silver J , Keerikatte V . Novel use of polymerase chain reaction to amplify cellular DNA adjacent to an integrated provirus [published erratum appears in J Virol 1990 Jun; 64 (6): 3150]. Journal of Virology1989; 63: 1924-1928 .
35.
35 Martin T , Parker SE , Hedstrom R , et al. Plasmid DNA malaria vaccine: the potential for genomic integration after intramuscular injection . Human Gene Therapy1999; 10: 759-768 .
36.
36 FDA CBER . Food and Drug Administration, Center for Biologics Evaluation and Research (1998). Guidance for industry: Guidance for human somatic cell therapy and gene therapy . Fed Register1998; 36413-36413 .
37.
37 Bauer SR . Use and abuse of PCR assays for vector biodistribution studies: an FDA perspective. Avail-able at http://www.fda.gov/cber/summaries/asgtO60999sb.ppt. 1999; (Abstract).
38.
38 Wang R , Doolan DL , Le TP , et al. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine . Science1998; 282: 476-480 .
